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6/j.bHY-specificT cells are presumed toplay a role in acute graft-versus-host disease (aGVHD) after female-to-male
stem cell transplantation (SCT). However, infiltrates of these T cells in aGVHD-affected tissues have not yet
been reported. We evaluated the application of HLA-A2/HY dextramers for the in situ detection of
HY-specific T cells in cryopreserved skin biopsy specimens. We applied the HLA-A2/HY dextramers on cry-
opreserved skin biopsy specimens from seven male HLA-A21 pediatric patients who underwent stem cell
transplantation with confirmed aGVHD involving the skin. The dextramers demonstrated the presence of
HY-specific T cells. In skin biopsy specimens of three male recipients of female grafts, 68% to 78% of all
skin-infiltrating CD81 T cells were HY-specific, whereas these cells were absent in biopsy specimens collected
from sex-matched patient–donor pairs. Although this study involved a small and heterogeneous patient group,
our results strongly support the hypothesis that HY-specific T cells are actively involved in the pathophysiology
of aGVHD after sex-mismatched stem cell transplantation.
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Acute graft-versus-host disease (aGVHD) is a life-
threatening complication of allogeneic stem cell trans-
plantation (SCT) mainly affecting the stem cell
recipient’s skin, liver, and/or gastrointestinal tract [1].
Matching the stem cell donor and recipient for HLA
significantly reduces the risk for aGVHD and chronic
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bmt.2011.10.038development of GVHD is caused by donor T cells spe-
cific for ubiquitously expressed minor histocompatibil-
ity antigens [3], such as the Y chromosome-encoded
HY antigens. Clinical results indicate that male recipi-
ents of female stem cells are at the greatest risk for
GVHD [4].
Previous reports on the presence of HY-specific
CD81 T cells in peripheral blood samples of adult
male patients who developed aGVHD after sex-
mismatched SCT [5,6] suggest the involvement of
these cells in the pathophysiology of GVHD. This
assumption is supported by results from in vitro
studies using an ex vivo in situ skin explant model in
which HY-specific cytotoxic T lymphocytes (TCTL)
cause GVHD-like tissue destruction when added
to male skin tissues expressing the relevant HY-
presenting HLA class I molecules [7]. However,
whether the presence of circulating HY-specific
CD81 T cells detected before and after the onset of
aGVHD reflects an active contribution of these cells
to tissue destruction has remained unclear.We applied
a dextramer-based staining technique to retrospec-
tively analyze the in situ presence of HLA-A2/HY–
specific CD81 T cells in archived cryopreserved skin
biopsy specimens from 7 HLA-A21male pediatric pa-
tients who developed aGVHD of the skin after381



















Minor H Antigen Mismatch in
Graft-versus-Host Direction
UPN 567 4 CML TBI, Cy, ATG F PBSC ND 12 16 (I) A2/HY, B60/HY, HA-1,
HA-8, ACC-2
UPN 473 7 SAA TAI, Cy, ATG F BM 100% 22 24 (I-II) A2/HY
UPN 463 6 X-ALD Bu, Cy, ATG F BM ND 13 14 (I-II) A2/HY, B8/HY
UPN 574 4 SAA Cy, Treo, ATG M BM 100% 14 16 (II) -
UPN 577 7 MDS RAEBII Bu, Cy, Mel, Cam1H M PBSC ND 12 14 (II) HLA- 2/LB-ADIR-1
UPN 501 7 X-LPD Bu, Cy, ATG M BM 100% 14 18 (I) HLA-A2/LB-ADIR-1
UPN 520 15 ALL TBI, Cy, VP16, ATG M BM 100% 35 39 (II) HLA-A2/HA-8
CML indicates chronic myelogenous leukemia; SAA, severe aplastic anemia; X-ALD, X-linked adrenoleukodystrophy; MDS RAEBII, myelodysplastic syn-
drome (refractory anemia with excess number of blasts); X-LPD, X-linked lymphoproliferative disease; ALL, acute lymphoblastic leukemia; TBI, total
body irradiation; TAI, thoracoabdominal irradiation; Cy, cyclophosphamide; ATG, anti thymocyte globulin; Bu, busulfex; Treo, treosulphan; Mel, melpha-
lan; Cam1H, Campath (alemtuzumab); VP16, etoposide; PBSC, G-CSF mobilized peripheral blood stem cells; BM, bone marrow; ND, not determined.
a
T cell depletion of the graft through antibody-induced T cell rosetting (UPN 463), purified CD34 with T cell add-back (UPN 567), or Campath ‘‘in the
bag’’ (UPN 577).
b
Percentage donor chimerism was determined by VNTR analysis (PowerPlex 16) on PBMCs collected between 21 and 28 days post-SCT.
c
Days after hematopoietic stem cell graft infusion, followed by the Lerner GVHD grading [11] in parentheses.
382 Biol Blood Marrow Transplant 18:381-387, 2012Y.-H. Kim et al.undergoing allogeneic HLA-matched unrelated SCT
with a male or a female donor.METHODS
Study Participants
All skin biopsy samples analyzed in this study were
derived fromHLA-A21male individuals and were col-
lected after written informed consent was obtained in
accordancewith theDeclaration ofHelsinki. Skin sam-
ples were collected from five healthy adult volunteer
donors and from seven pediatric patients who under-
went allogeneic SCT for the treatment of various
hematologic and nonhematologic disorders (Table 1).
Patient selection was based on the expression of
HLA-A2 by patient and donor, the development of his-
tologically confirmed aGVHD [8] involving the skin
and the availability of a cryopreserved skin biopsy spec-
imen collected before the initiation of first-line treat-
ment with corticosteroids. All but two patients (UPN
567 and UPN 577) received a 10/10-matched (HLA-
A, -B, -C, -DQ, and -DR) stem cell graft from an unre-
lated donor. Three of the seven male patients (UPN
567,UPN473, andUPN463) received a stem cell graft
from a female donor. The use of peripheral blood
mononuclear cells (PBMCs) and skin samples for the
underlying study was approved by Leiden University
Medical Center’s Medical Ethics Committee.
Multimeric HLA Class I Peptide Complexes
Conventional allophycocyanin (APC)-conjugated
HLA-A2 tetramers and phycoerythrin (PE) conjugated
HLA-A2 dextramers (Immudex, Copenhagen, Den-
mark), both containing theHLA-A2–restrictedHYpep-
tide FIDSYICQV (designated as HLA-A2/HY
tetramersorHLA-A2/HYdextramers), aswell as control
PE-conjugated HLA-A2 dextramers containing the
influenza peptide GILGFVFTL (HLA-A2/fludextramers) were prepared as described previously
[6,9,10]. The specificity and sensitivity of these HLA-
A2/peptide multimers were routinely determined by
fluorescent activation cell sorting analysis
(SupplementaryFigureS1), asdescribedpreviously [6,9].Immunofluorescent Staining and Confocal
Laser Scanning Microscopy Analysis of
Cryopreserved Skin Explant Tissue and
aGVHD-Affected Skin Tissue
Before cryopreservation, skin explant assays were
performed with freshly obtained healthy male skin
biopsy specimens that were coincubated in vitro for 72
hours at 37C and 5% CO2 with 1  106 HY-specific
TCTL, as described in detail elsewhere [7,11]. Control
skin biopsy specimens, prepared from the same healthy
donors, were incubated with HLA-A2/HA-1–specific
TCTL. Of note, the latter T cells infiltrate human skin
in the presence of HA-11 dendritic cells [12], but unlike
the HY-specific TCTL, HA-1–specific TCTL do not
cause GVHD-like tissue destruction [7,12].
Cryosections (6 mm) were prepared from both snap-
frozen skin explant tissue and cryopreserved aGVHD-
affected skin biopsy specimens. After acetone fixation,
the sections were stained at 4C with PE-conjugated
HLA-A2/HY dextramers or control PE-conjugated
HLA-A2/Flu dextramers, followed by appropriately di-
luted rabbit anti-PE antibody (Biogenesis, Poole,
United Kingdom) and cyanin 3-labeled goat anti-
rabbitF(ab)2 antibody (Jackson ImmunoResearchLabo-
ratories, West Grove, PA). All cryosections analyzed in
this study (from volunteer donors and from SCT pa-
tients) were simultaneously stained with FITC-
conjugatedCD8antibody (BeckmanCoulter,Woerden,
The Netherlands) [11]. Combined immunofluorescent
staining using antibodies specific for CD3 (Dako,
Glostrup, Denmark) CD4 (Neomarkers via Immuno-
logic, Duiven, The Netherlands), CD8 (Novocastra
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lands) or CD8 (Beckman Coulter)/CD45RO (Dako)/
granzyme B (Sanquin, Amsterdam, The Netherlands)
was performed as described previously [11,13]. All
sections were mounted with vectashield (Vector
Laboratories, via Reactolab SA, Servion, Switserland)
and analyzed on a Leica TCS SP confocal laser
scanning system (Leica Microsystems B.V).
Images were collected sequentially using a 40 
numerical aperture 1.4 objective. Color photographs
were generated as electronic overlays. For each patient
exceptUPN520, between four and 18 consecutive cry-
osections were scored for the presence of CD81HLA-
A2/HY dextramer-negative and CD81 HLA-A2/HY
dextramer-positive T cells. A single section prepared
from a biopsy specimen from UPN 520 was scored
in a similar way. Each section consisted of five to seven
confocal images of 512 mm  512 mm  6 mm (W 
L  H) each, covering the complete section. All posi-
tively staining cells were individually analyzed while
scanning in the z-axis direction to obtain a three-
dimensional confocal image window, to exclude inclu-
sion of noncellular structures in the total number of
positive cells counted in nearly the complete biopsy.
Statistical Analysis
In each patient, the mean number of HLA-A2/HY
dextramer-positive CD81 T cells per cryosection was
calculated. Differences between the mean values
observed in the biopsy specimens of sex-matched and
sex-mismatched recipients were analyzed by a two-
tailed unpaired t-test using GraphPad Prism version
5.00 for Windows (GraphPad Software, La Jolla, CA).RESULTS
Onset of aGVHD Coincides with an Increase in
Peripheral Blood Lymphocytes
All patients exhibited the first clinical symptoms of
aGVHD in the skin between 12 and 35 days after SCT
(Table 1). Results on post-SCT peripheral blood lym-
phocyte recovery were available in six of the seven pa-
tients (Supplementary Figure S2). The missing data
for UPN 577 were due to early death, at day115 after
SCT. Although total peripheral blood lymphocyte
counts were not in the range of those obtained before
SCT (27456 809/mL), all six patients displayed an in-
crease in absolute numbers of lymphocytes at or
shortly after the day of skin biopsy collection (range,
80-1073/mL). CD41 and CD81 T cell subset analysis
was performed on blood samples collected shortly be-
fore and after onset of aGVHD from UPN 567, UPN
574, UPN 501, and UPN 520. In line with data on to-
tal lymphocyte counts measured in parallel, both
CD41 and CD81 T cell counts were increased after
the onset of aGVHD. Sufficient numbers of PBMCsfrom UPN 567 and UPN 473 (both male recipients
of a female stem cell graft) were available for additional
HLA-A2/HY tetramer analysis performed at 2 and 4
weeks (UPN 567) or 4 and 5 weeks (UPN 473) after
SCT. The numbers of HY-specific T cells in CD81
cell fractions were below the detection limit in all
four PBMC samples analyzed (data not shown). Chi-
merism analyses performed on PBMC samples col-
lected 21 to 28 days after SCT revealed complete
donor origin in four (UPN 473, UPN 574, UPN
501, and UPN 520) of six patients (Table 1).
Validation ofHLA-A2/HYDextramers for in Situ
Detection of HY-Specific T Cells in
Cryopreserved Skin Explant Tissue
Failure to detect circulating HY-specific CD81
T cells after the onset of aGVHD in lymphopenic
sex-mismatched recipients does not exclude their pos-
sible presence in aGVHD-affected tissues. Thus, we
analyzed archived frozen skin biopsy specimens from
our patient cohort. Because the conventional HY tet-
ramers do not stain frozen biopsy specimens [11], we
first validated HLA-A2/HY dextramers on frozen
sections prepared from ex vivo in situ skin explant tis-
sue for their selective staining capacities [7,11]. To this
end, HLA-A2/HY–specific TCTL or control HLA-A2/
HA-1–specific TCTL were added exogenously to fresh
skin tissue derived from HLA-A21 healthy male
volunteer donors. Similar to conventional HLA-A2/
HY tetramers [11], HLA-A2/HY dextramers stained
skin-infiltrating HY-specific TCTL when applied to vi-
able skin explant tissue that was snap frozen after the
addition of either staining reagent (data not shown).
However, in the clinical setting of pediatric SCT,
obtaining fresh tissue biopsy specimens for such exper-
iments is difficult. Therefore, we analyzed the capacity
of HLA-A2/HY dextramers to stainHY-specific TCTL
when applied to already cryopreserved tissue. HLA-
A2/HY dextramers, in contrast to HLA-A2/HY tetra-
mers, were able to stain HY-specific TCTL when
applied to cryosections prepared from snap-frozen
skin explant tissue (Figure 1A). Control HLA-A2/Flu
dextramers did not label skin-infiltrating HY-specific
TCTL (Figure 1B). Furthermore, HLA-A2/HY dex-
tramers did not stain cryosections preincubated with
HA-1–specific TCTL (Figure 1C). Collectively, these
results show the specificity and applicability of HLA-
A2/HY dextramers to visualize HY-specific CD81
T cells in cryopreserved skin tissue collected for clini-
cal evaluation.
Presence of HY-Specific CD81 T Cells in
aGVHD-Affected Skin collected from Male
Recipients of Female Stem Cell Grafts
Historically collected cryopreserved skin biopsy
specimens from seven pediatric patients with
Figure 1. In situ staining of skin-infiltrating CD81 T cells reveals the presence of both granzyme B1 and HLA-A2/HY dextramer-positive cells in
aGVHD-affected skin tissue obtained after female-to-male SCT. Skin explant tissue derived from healthy male HLA-A21 volunteer donors was used
to validate the sensitivity and specificity of HLA-A2/HY dextramers (red) for combined in situ labeling of skin-infiltrating CD81 T cells (green). These
skin segments were incubated with either HY-specific TCTL (A and B) or control HA-1–specific TCTL (C) before cryopreservation and immunofluores-
cent labeling. Double-labeled cells, which are HY-specific CD81 T cells, become yellow in the overlay illustrations, as depicted by the representative cell
in the lower right overlay insert of (A). Single-labeled cells (ie, CD81 cells) remain green in the overlay pictures, as depicted by the representative cells in
the lower right insert of (B) and (C). (D and E) Combined immunofluorescent staining of cryosections prepared from aGVHD-affected skin biopsy spec-
imens obtained from two male recipients of a female graft (D, UPN 473; E, UPN 567). The cryosections were incubated with HLA-A2/HY dextramers
(red) and CD8 antibodies (green). Yellow arrows indicate colocalization of HLA-A2/HY dextramers and CD8 antibodies on the same cell. (F) Combined
CD8 (green), CD45RO (dark blue), and granzyme B (red) staining in a cryosection prepared from the same individual as shown in (E). (G and H) The
identical staining procedure as described in (D) and (E) but applied to cryosections obtained from two male recipients of a male graft (G, UPN 501; H,
UPN 574). Green arrows indicate CD81 cells not expressing the T cell receptor that specifically binds HLA-A2/HY dextramers. The higher magnifi-
cation of a representative single-labeled cell in (E) depicts a CD81 TCTL that is not HY-specific. Note that keratinocytes located at the dermal–epidermal
junction may display some nonspecific red staining when incubated with dextramer preparations. (I) Combined CD8 (green), CD45RO (dark blue), and
granzyme B (red) staining in a cryosection prepared from the same individual shown in (E).


















































































































































Figure 2. Acute GVHD after female-to-male SCT is associated with significantly higher numbers of skin-infiltrating CD81 T cells containing a high
percentage of cells specific for HY. (A) Total numbers of CD81 cells (left) and HLA-A2/HY dextramer-positive CD81 cells (right) were counted in
1-18 serial cryosections prepared from the same cryopreserved skin biopsy specimen collected shortly after clinical onset of aGVHD and before
the start of first-line treatment. All positively staining cells were individually analyzed while scanning in the z-axis direction to obtain a three-
dimensional confocal image window, to avoid inclusion of noncellular structures in the total number of positive cells counted in nearly the complete
biopsy specimen. For each individual patient, the box-and-whisker plot shows the mean number 6 SD of cells counted per section as indicated on
the y-axis. The upper and lower ends of the boxes represent the upper and lower quartiles, respectively. Whiskers represent the lowest and highest
observations. The solid line represents the median. *P\.05. (B) Percentage of HLA- A2/HY-specific T cells within the CD81 population in the three
female-to-male SCT recipients.
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analysis. The validated HLA-A2/HY dextramers
were used to analyze these cryosections. The presence
of HY-specific TCTL, visualized by HLA-A2/HY dex-
tramer and CD8 costaining cells, was found in two
of the three male recipients of a female stem cell graft
(Figure 1D and E). Higher-magnification images of
two double-positive cells are shown in the insert at
the bottom of Figure 1E. Of note, skin-infiltrating
HY-specific T cells were observed in biopsy specimens
collected as early as 12 to 13 days after sex-mismatched
SCT (UPN 463 and UPN 567). These T cells accu-
mulated at the same location as HY-specific CTL
clones applied in the skin explant assay [7], that is in
the dermis as well as just below the dermal–epidermal
junction (Figure 1D and E). At the same location,
granzyme B-coexpressing CD81 cells were visualized
(Figure 1F), illustrating that aGVHD skin-infiltrating
CD81 T cells are ‘‘licensed to kill’’ and are not inno-
cent bystanders. Unfortunately, the only available
HLA-A2/HY dextramers and the granzyme B-specific
antibody were both conjugated with PE, hindering
the analysis of coexpression of these two markers by
the same CD81 T cell.
CD81 HLA-A2/HY dextramer-positive T cells
were not detected in any of the biopsy specimens ob-
tained from male recipients of a male stem cell graft
(Figure 1G and H). These cryosections contained
only a few CD81 T cells, as exemplified by the en-
larged single positive green cell shown at the bottom
of Figure 1H. But these CD81 cells were notHY-specific and did not express granzyme B, in sharp
contrast to the skin-infiltrating CD81 cells shown in
Figure 1F. Control staining of serial sections with
HLA-A2/Flu dextramers revealed no positive signal
in any of the biopsy tissues tested (data not shown).
Quantification of the CD81 T cell infiltrates was
performed on skin biopsy specimens from all seven pa-
tients (Figure 2). Significantly higher numbers of
CD81 HY-specific T cells infiltrated the skin after
sex-mismatched SCT than after sex-matched SCT
(P\ .05) (Figure 2A). In contrast to the biopsy speci-
mens obtained after sex-matched SCT, high propor-
tions (68%-78%) of aGVHD skin-infiltrating CD81
cells in the male recipients of a female graft were
HY-specific (Figure 2B).DISCUSSION
HY-specific T cells may contribute to the develop-
ment of GVHD in male recipients of female hemato-
poietic stem cell grafts [14]. Although numerous
clinical studies have shown the influence of sex mis-
matching on SCT outcome, the in situ presence of
HY-specific T cells in GVHD-affected tissues has
not been shown until now. The available tetrameric
HLA HY peptide complexes do not stain infiltrated
T cells in cryopreserved tissues.
In this study, we first validated the use of dextra-
meric HLA-A2/HY peptide complexes using an
ex vivo skin explant model [7] with cryopreserved
386 Biol Blood Marrow Transplant 18:381-387, 2012Y.-H. Kim et al.skin tissues of healthy male individuals. The newly de-
veloped dextrameric HLA-A2/HY peptide complexes
allowed staining and analysis of infiltrating T cells in
cryopreserved tissues. These results thus allowed us
to perform a retrospective analysis of earlier stored
clinical GVHD samples.
For the first time, using dextrameric HLA-A2/HY
peptide complexes, we visualizedHY-specific CD81T
cells in aGVHD-affected tissue obtained from male
recipients of female stem cell grafts. Application of
the PE-labeled dextrameric HLA-A2/HY complexes
combined with CD8-specific antibodies showed skin-
infiltrating HY-specific T cells in cryopreserved skin
biopsy specimens obtained shortly after clinical mani-
festation of aGVHD in three male pediatric recipients
of a female stem cell graft. Despite the first signs of
lymphocyte recovery in the circulation, HY-specific
T cells were not detected in peripheral blood samples
collected from two of these three SCT recipients
(UPN 567 and UPN 473) at 2 to 5 weeks after SCT.
In previous work, we reported the presence of HY-
specific T cells in the peripheral blood of adult male
SCT recipients who developed aGVHD after receiv-
ing a non–T cell–depleted bone marrow graft from
a female donor [6]. These seemingly contradictory
results might be related to the significant differences
in applied SCT protocols between pediatric and adult
patients, such as composition of the applied stem cell
grafts and the pre- and post-SCT applied immune sup-
pression regimens. Of note, severe lymphopenia in the
first fewweeks after SCT, in combination with the lim-
ited volume of peripheral blood routinely collected
from pediatric SCT patients, has hampered reliable
HLA-A2/HY tetramer analyses in PBMCs. Thus,
our analysis was limited, as two of the three pediatric
male recipients of female grafts could be analyzed.
Note, however, that we found a relatively high number
of HY-specific T cells migrating to the skin during the
early stage of aGVHD. Whether or not this clarifies
the absence of minorHY-specific T cells in the periph-
eral blood is a subject for extensive future analysis.
Given that TCR stimulation-induced cell cycle
progression is required for the induction of granzyme
B-containing cytolytic granules in both na€ıve and
antigen-experienced TCTL [15], the presence of highly
granzyme B1CD81 in aGVHD-affected skin suggests
that these presumably cytolytic T cells are activated.
As shown in Figure 1F, activated TCTL ultimately
release their cytolytic granules in the dermis or at the
dermal–epidermal junction. At the same location,
GVHD-like tissue destruction occurs in vitro when
HY-specific TCTL clones are applied in the skin
explant assay [7]. We previously demonstrated that
HLA-A2/HY-specific TCTL clones lyse IFN-g–acti-
vated HLA-A21 epidermal keratinocytes in vitro
[16]. In vivo, IFN-gmay be derived from the activated
TCTL themselves and/or from activated, that is,CD45RO expressing CD41 T cells present in the
same dermal infiltrates (Figure 1F).
The early appearance ofHY-specific CD81T cells
in aGVHD-affected skin raises the question whether
these T cells arise from na€ıve or memory T cells,
both ofwhich are likely cotransferred alongwith the fe-
male hematopoietic stem cell graft into the male pa-
tient. Although we were not able to analyze pre-SCT
collected female donor PBMCs in the present study,
it should be noted that pregnancy can induce the gen-
eration and long-term persistence of minor histocom-
patibility antigen-specific TCTL, including T cells
specific forHY [17-19]. It is possible that suchmemory-
type minor histocompatibility antigen-specific T cells
are also present in hematopoietic stem cell products
prepared from parous female donors. On reencounter-
ing the relevantminor histocompatibility antigen in the
stem cell recipient, these T cells may contribute to the
development of aGVHD. Prospective analyses of the
presence of cytolytic type T cells specific for ubiqui-
tously expressed minor histocompatibility antigens in
female stem cell products may identify SCT patient–
donor pairs at risk for aGVHD.
In conclusion, the present study provides the first
indication that HY-specific T cells are actively in-
volved in the development of aGVHD after sex-
mismatched SCT. The size of our study population
was small and the patient population relatively hetero-
geneous, however, and further studies on larger and
more homogeneously treated patients are needed to
evaluate the clinical significance of our observations.ACKNOWLEDGMENTS
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